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etabolic Syndrome
nd Cardiovascular
bnormalities in Children*
tephen R. Daniels, MD, PHD, FACC
enver, Colorado
he clustering of risk factors for cardiovascular disease,
articularly in the presence of obesity, has been recognized
or some time. Reaven (1) first called this syndrome X. The
ommon factors in this cluster are obesity, usually central
besity, increased blood pressure, lipid abnormalities, and
ncreased fasting glucose. Since the initial description, a
umber of definitions have been proposed, but the one most
idely used is that of the National Heart, Lung, and Blood
nstitute National Cholesterol Education Program in the
dult Treatment Panel III report (2). In this report, the
oncept of the metabolic syndrome was to characterize the risk
f cardiovascular disease associated with obesity beyond that
ssociated with elevation of low-density lipoprotein choles-
erol and serve as a complement to the Framingham Risk
core for adults. The metabolic syndrome has been found to
e associated with increased risk of development of cardio-
ascular disease and type 2 diabetes mellitus.
See page 932
There have been both proponents and opponents to the
etabolic syndrome concept in adults (3–6). The propo-
ents have emphasized that the syndrome predicts increased
isk of type 2 diabetes mellitus and cardiovascular disease.
he opponents have indicated that although a cluster may
xist from an epidemiologic standpoint, the pathophysiol-
gy underlying the metabolic syndrome remains unclear.
his is one reason why it is called a syndrome. This also
eans there is no treatment for the metabolic syndrome
ther than weight loss. Opponents have also argued that
here is no clear case for the metabolic syndrome cluster
perating independent of its component parts. Physicians
re left to treat the individual components of the syndrome.
owever, some components, such as hypertension, are more
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.d
From the Department of Pediatrics, University of Colorado Denver, School of
edicine, Denver, Colorado.menable to treatment than others, such as low high-density
ipoprotein cholesterol or increased triglycerides. Still others
ave been concerned about the marked differences by
ender or ethnic group in the prevalence of metabolic
yndrome and the frequency of variables that make up the
etabolic syndrome that are likely to be abnormal.
The issues regarding the metabolic syndrome in children
nd adolescents are even more complex. First, the link
etween cardiovascular disease risk factors and the develop-
ent of clinical cardiovascular disease is much harder to
stablish because of the long timeline between things that
ccur in childhood and clinical outcomes that do not occur
ntil later in adulthood. The questions remain concerning
hich are key variables in the metabolic syndrome for a
oung person. In addition, because children and adolescents
re growing and developing, it is impossible to choose a
ingle cutpoint for a risk factor variable. This problem has
ed to the use of percentiles, but it remains difficult to
etermine what percentile value to use as a cutpoint. In
ddition, it is not clear whether percentile values should be
erived from children studied at the present time, when
besity is quite prevalent (approximately 17%) or from
opulations of children before the onset of the obesity epi-
emic. Despite these difficulties, numerous investigators have
ttempted to develop a definition for metabolic syndrome.
s might be expected, with each different definition, there
re differences in the prevalence of metabolic syndrome.
It is against this backdrop that Chinali et al. (7) per-
ormed the analyses presented in this issue of the Journal on
hildren from the Strong Heart Study. They set out to
nswer 2 important questions: 1) Is the metabolic syndrome
ssociated with cardiovascular abnormalities such as left
entricular hypertrophy and left atrial enlargement in ado-
escents? 2) Does the presence of the metabolic syndrome
ave ability to independently explain the variance of cardio-
ascular abnormalities after the individual components have
een considered? Their analyses provide a potentially im-
ortant “yes” to answer each question.
Chinali et al. (7) used 2 definitions of the metabolic
yndrome. The first is the adult definition from the National
holesterol Education Program in the Adult Treatment
anel III report (2). This approach can be seen as a very
onservative one because adult values for waist circumfer-
nce, blood pressure, and lipid abnormalities set a high bar
ven for adolescents. The second definition is one that uses
ercentile values by age and gender and is designed to be
ore applicable to use in children and adolescents (8).
ndeed, Chinali et al. (7) found that the prevalence of the
etabolic syndrome was greater when they used the pedi-
tric percentile-based definition of Jolliffe and Janssen (8)
ompared with the adult definition. It is interesting, how-
ver, that further results regarding associations between the
etabolic syndrome and cardiovascular outcome variables
ere generally similar and did not depend on which
efinition was used.
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Editorial Comment September 9, 2008:939–40Chinali et al. (7) found that the prevalence of dilation of
he left atrium and left ventricular hypertrophy were sub-
tantially greater in the adolescents with metabolic syn-
rome compared with those without it. These dependent
ardiovascular variables are important in the study of ado-
escents. Left ventricular hypertrophy has been shown to be
n independent risk factor for cardiovascular disease in
dults (9). Left atrial enlargement has been shown to be
ssociated with an increased risk of cerebrovascular disease
n adults (10). Both left ventricular hypertrophy and left
trial enlargement have been found in children and adoles-
ents with obesity and hypertension and are thought to
epresent evidence of early adverse impact of those factors
n the cardiovascular system (11,12). They are useful
urrogate end points at an age during which true clinical
ardiovascular outcomes are uncommon. The findings of
hinali et al. (7) support the concept that the metabolic
yndrome is already having an adverse effect even in ado-
escence. However, it is well known that obesity and blood
ressure increases are associated with increased left atrial
ize (12) and increased left ventricular mass index (11).
hinali et al (7) also found that the presence of the
etabolic syndrome as a cluster of variables was indepen-
ently associated with left atrial enlargement and with left
entricular hypertrophy, even after controlling for the indi-
idual metabolic syndrome variables that had significant
ssociations. This finding is a new and potentially important
ne and suggests that the metabolic syndrome as a cluster of
ariables may have biologic and perhaps clinical importance
or cardiovascular outcomes.
There are some important caveats to consider. The
trong Heart Study cohort is valuable because it has been
ell-characterized. However, it is limited in that it includes
nly Native American subjects. The findings of Chinali
t al. (7) will need to be validated in other populations. The
ean age for the participants of this study was 17 years, and
nly 2 of the subjects were younger than 15 years of age,
hich means that most subjects were past the stage of sexual
aturation. This fact clearly limits the ability of one to
eneralize the findings to younger adolescents and children.
n addition, this study was a cross-sectional one, which is
mportant because Goodman et al. (13) have reported that
he diagnosis of metabolic syndrome in adolescents is
elatively unstable. Further longitudinal studies will be
eeded in this and other cohorts to evaluate whether the
elationships observed are stable over time. This will be an
mportant aspect of determining the clinical utility of the
ndings reported.
Although the concept of the metabolic syndrome remains
ontroversial, there can be no question that finding im-
roved methods of determining which children and adoles-
ents are at greatest risk of type 2 diabetes and cardiovas-
ular disease would be useful. This determination would Kllow clinicians to implement more-aggressive lifestyle in-
ervention in these patients and possibly initiate pharmacol-
gic intervention when necessary. The current epidemic of
besity and the increase in prevalence of type 2 diabetes
ellitus in adolescents makes the ability to identify these
reater-risk children and adolescents even more important.
he report by Chinali et al. (7) improves our understanding
f these risk factors on the cardiovascular system and
uggests that it may be useful to consider how these risk
actors cluster as a metabolic syndrome in young individuals.
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